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Cisplatin is a first-line chemotherapeutic for the treatment of a wide variety of cancers since 
its discovery in the 1960s. Although various techniques have been reported for the 
measurement of total platinum in biological matrices, such as inductively coupled plasma-
mass spectrometry and derivatization procedures, a specific, sensitive and robust assay for 
the quantification of intact cisplatin is still lacking. Therefore, we present a rapid, selective, 
sensitive, and reliable UHPLC-MS/MS based method for the determination of intact cisplatin 
in human plasma in support of a Phase II clinical trial. The optimal chromatographic behavior 
of cisplatin was achieved on a Syncronis HILIC column (50 x 2.1 mm, 1.7 µm, zwitterionic 
stationary phase). The retention behavior of cisplatin on this zwitterion-based stationary 
phase was well described by an adsorptive interaction model. A simple sample preparation 
based on protein precipitation combined with the removal of phospholipids by HybridSPE-
precipitation was developed. The method was proven to be free of a relative matrix effect. 
The assay was validated within a range of 20 - 10000 ng/mL using 100 µL of plasma sample. 
The intra and inter-day precisions were all less than 7.6 %, and none of the bias was greater 
than 13.1 %, thus corroborating that the developed method is precise and accurate. As a 
proof of concept, the assay has been successfully applied to plasma samples obtained from 





















Platinum (Pt) drugs are coordination complexes of platinum with multiple inorganic or organic 
ligands with cisplatin being the simplest platinum drug in which the Pt atom is associated with 
two amine and two chlorine leaving ligands[1]. As the first chemotherapeutic agent that was 
used clinically since 1970[2, 3], cisplatin still holds a leading position for the treatment of 
various types of solid tumors (head and neck, ovarian, gastric, lung, bladder, and testicular, 
etc.)[4-6]. It is well known that cisplatin is partly hydrolyzed to a monohydrated complex 
(MHC) upon administration[7, 8], and that both cisplatin and MHC undergo irreversible ligand 
exchange reactions with biological nucleophiles such as nucleotides, methionine, glutathione, 
and albumin[9, 10]. Both cisplatin and MHC are responsible for the antitumor effects as well 
as the toxic side effects (e.g. nephrotoxicity)[7, 11]. After ligand exchange, the 
biotransformed platinum products are no longer biologically active[10, 12].  
 
Numerous analytical methodologies have been developed in the last decades for the 
determination of cisplatin[13, 14]. However, quantitative determination of MHC is scarcely 
reported due to the lack of a pure standard of MHC. Some studies reported the 
measurement of MHC using the hydrolysis equilibrium solution of cisplatin in distilled 
water[15, 16]. However, as found in an exhaustive mass spectroscopic hydrolysis study[17], 
the hydrolysis equilibrium approach presented in literatures does not provide a reliable way 
of obtaining a standard with a traceable exact amount of MHC useful for calibration 
purposes. This essentially prohibits a quantitative MHC measurement despite the analytical 
potential of the sample treatment, chromatographic and detection. 
 
Bioanalytical determination of cisplatin is most often based on non-selective techniques, 
targeting the Pt, which cannot distinguish between different Pt-containing complexes. These 
non-selective techniques include phosphorescence[18], X-ray fluorescence[19], atomic 
absorption spectroscopy (AAS)[20-22] and inductively coupled plasma-mass spectrometry 
(ICP-MS)[23-25]. ICP-MS is the most frequently used tool for the measurement of total 
platinum for the drug cisplatin[14, 26]. However, circulating total platinum represents a 
mixture of platinum species, with differing biological activity and toxicity profiles. Thus, the 
amount of total platinum does not reflect the authentic concentration of intact cisplatin and/or 
MHC and could lead to erroneous interpretations of the clinical pharmacokinetics and 
pharmacodynamics of cisplatin. 
 
Selective methods for the determination of cisplatin itself in biological matrices are based on 
HPLC followed by different kinds of on-line or off-line detectors such as radioactivity 
detection[27], UV detection[10, 16, 28-30], flameless atomic absorption spectrometry 
(FAAS)[15], ICP-MS[31-34] and MS/MS[35]. UV-based methods usually require pre-column 
or post-column derivatization due to the low molar absorptivity of cisplatin in the UV 
spectrum[10, 28-30, 36]. Pre-column derivatization is a sensitive, yet unselective approach 
because of the formation of the same derivatization product for cisplatin, MHC as well as 
other Pt-based complexes (e.g. Pt-methionine and Pt-glutathione). This leads to an 
overestimation of the concentration of intact cisplatin in biological samples[37]. Post-column 
derivatization requires a microwave-assisted heater system and enormous efforts to maintain 
the sensitivity and robustness of the method[10, 16]. HPLC with off-line detection such as 
FAAS requires tedious collection of different fractions and is therefore of limited use in 
medium to high-throughput applications[15]. HPLC-ICP-MS is a sensitive technique for the 
measurement of cisplatin in biological matrices, such as plasma ultrafiltrate, by detecting the 
specific mass of platinum[31-33]. However, chromatographic separation is still a requirement 
to provide satisfactory specificity and the particular hyphenated technique is not readily 
available in regular bioanalytical labs. 
 
LC-MS/MS is a highly selective, reliable and sensitive methodology for the quantitation of 
analytes in biological samples by using specific precursor-to-product ion transitions. Previous 
studies have shown promising applications of LC-MS/MS for the determination of Pt-based 
drugs such as carboplatin[38] and oxaliplatin[39]. However, only poorly detectable ions were 
found for cisplatin regardless of the types of acid modifiers and solvents employed[1, 2, 8, 
40], reflecting the analytical challenges for direct quantitation of cisplatin using LC-MS/MS. 
Several studies have reported the use of pre-column derivatization of cisplatin for LC-MS/MS 
quantitation[41-43]. Although this approach can promote the ionization of cisplatin, it results 
in a measurement of cisplatin together with other Pt-based complexes aforementioned. To 
our knowledge, only one LC-MS/MS method has been described for the quantification of 
intact cisplatin in rat kidney and liver[35].  
 
Reliable determination of intact cisplatin in biological samples is not easy since cisplatin can 
rapidly react with nucleophilic species in the matrices[44] and undergoes hydrolysis in 
aqueous medium[8]. Most of the bioanalytical work on cisplatin was done in plasma[16, 31] 
or blood ultrafiltrate[10]. The aim here is to remove, and consequently reduce cisplatin 
interaction with, proteins. However, this does not alleviate the instability of cisplatin in the 
aqueous environment of the ultrafiltrate: cisplatin is also highly susceptible to hydrolysis. The 
above mentioned LC-MS/MS assay uses a conventional liquid-liquid extraction followed by a 
tedious evaporation procedure[35]. As such,  it does not meet the requirements for a high 
throughput determination of cisplatin in biological fluids such as plasma.  
 
Intraperitoneal chemoperfusion (IPEC) is a type of normothermia or hyperthermia therapy 
used in combination with surgery in the treatment of advanced abdominal cancers[45]. In this 
procedure, (warmed) anti-cancer drugs are infused and circulated in the peritoneal cavity for 
a short period of time. In support of the assessment of the efficacy of cisplatin-based IPEC in 
cancer patients, a simple, reliable, and high throughput assay for the determination of intact 
cisplatin in human plasma is appreciated. Therefore, the aim of this study was to develop 
and systematically validate a selective and sensitive UHPLC-MS/MS assay for the 
measurement of intact cisplatin in human plasma. As a proof of concept, this method was 
subsequently used to quantify cisplatin in plasma samples from an IPEC study in patients 
with peritoneal carcinoma receiving intraperitoneal chemoperfusion of cisplatin. We think that 
the method developed presents a new strategy for the direct determination of Pt-based drugs 
in complex biological matrices, such as plasma.  
2. Experimental 
2.1 Reagents and chemicals 
Cisplatin and dichloro(ethylenediamine)platinum(II) (internal standard, IS) standards were 
purchased from European Directorate for the Quality of Medicines Council of Europe and 
Sigma-Aldrich (Belgium), respectively. Ultra liquid chromatography-MS (ULC-MS) grade 
water and acetonitrile were obtained from Biosolve (Valkenswaard, The Netherlands). Formic 
acid, ammonium formate and HybridSPE®-Plus 96-Well Plates (50 mg/well, volume 2 mL) 
were supplied from Sigma-Aldrich (Brussels, Belgium). All other chemicals were of analytical 
grade. Li-heparinized human plasma was purchased from Seralab (West Sussex, United 
Kingdom). 
 
2.2 Instrumentation and set-up 
Chromatographic separation of cisplatin was evaluated on several HILIC columns including 
an Acquity BEH HILIC column (50 × 2.1 mm, 1.7 μm) from Waters (Milford, MA, USA), a 
SeQuant ZIC-HILIC column (100 x 2.1 mm, 3.5 µm, zwitterionic stationary phase) from 
Millipore (Umeå, Sweden), and a Syncronis HILIC column (50 x 2.1 mm, 1.7 µm, zwitterionic 
stationary phase) from Fisher Scientific (Aalst, Belgium). Reversed-phase columns including 
an Acquity BEH C18 column (50 × 2.1 mm, 1.7 μm) and an Acquity HSS T3 column (50 × 2.1 
mm, 1.7 μm) from Waters (Milford, MA, USA) for reversed-phase chromatography were also 
tested during method development. For method validation and sample analysis, the 
chromatographic analysis was performed on the Syncronis HILIC column installed in an 
Acquity UHPLC H-class system (Waters, Milford, MA). The mobile phase (MP) consisted of 
MP A (10/85/5 acetonitrile/water/50 mM ammonium formate buffer, pH 3.75) and MP B (95/5 
acetonitrile/50 mM ammonium formate buffer, pH 3.75). Compounds were eluted using the 
conditions shown in Table 1 with a divert valve switched alternatively between detector and 
waste as follows: 0-0.6 min: to waste; 0.6-1.25 min: to detector; 1.25-5.0 min: to waste. The 
column temperature was maintained at 45 °C, and the injection volume was 2 μL.  
 
Eluted components were detected using a Waters Xevo TQS tandem mass spectrometer 
(Waters, Milford, MA) operated in positive electrospray ionization (ESI+) mode. The optimized 
instrument conditions were as follows: electrospray capillary voltage 4.0 kV, cone voltage 25 
V, and source temperature of 125°C. The desolvation gas (nitrogen) flow rate was set to 
1000 L/h at a temperature of 500 °C, and collision gas (argon) flow was maintained at 0.15 
mL/min. The collision energy was set at 14 eV for both cisplatin and 
dichloro(ethylenediamine)platinum(II). Cisplatin and dichloro(ethylenediamine)platinum(II) 
were detected in the multiple reaction monitoring (MRM) mode with a dwell time of 0.146 s 
per transition. The MRM transitions were m/z 318.1 > 265.0 for cisplatin, and m/z 344.0 > 
291.0 for dichloro(ethylenediamine)platinum(II).  
 
2.3 Preparation of standards and quality controls 
A stock solution of cisplatin at a concentration of 0.5 mg/mL in 0.9% sodium chloride was 
prepared and stored at 4 °C. This stock solution was further appropriately diluted with 0.9% 
sodium chloride to produce working solutions (ranging from 0.4 - 200 μg/mL) for calibrator 
samples. The working solutions for quality control (QC) samples were prepared at four 
concentrations (0.4, 1, 10 and 160 μg/mL) and were diluted from a separate stock solution. 
The IS stock solution (0.2 mg/mL) was also prepared in 0.9% sodium chloride and was 
further diluted to a concentration of 5 μg/mL.  
 
95 μL of drug-free plasma samples were spiked with corresponding 5 μL working solutions to 
obtain calibrators and QC samples.  
 
2.4 Sample processing 
A volume of 100 μL of each plasma sample was added onto the HybridSPE-Plus plate. 
Subsequently, 10 μL of a 5 μg/mL IS working solution was pipetted into each well. 
Afterwards, 300 μL ice-cold acetone containing 0.1% formic acid was added to each well, 
and the wells were aspirated repeatedly using a multi-chanel pipette. After mixing, vacuum 
was applied for 8 min and the resulting filtrate was collected for injection.   
 
2.5 Method validation 
The method was fully validated according to the “Guideline on bioanalytical method 
validation” released by European Medicines Agency (EMA), 2011. QC samples at four 
concentration levels (20, 50, 500, and 8000 ng/mL) were freshly prepared and analyzed in 
separate batches.  
 
Selectivity was assessed by evaluating peak inferences from six individual sources of blank 
plasma. Interferences were considered negligible if the response is less than 20% of the 
lower limit of quantification (LLOQ) for cisplatin and 5% for the IS. Bias and imprecision were 
assessed from QC’s that were analyzed in 6 replicates at four concentration levels on 3 
different days. Bias was determined as % relative error of nominal concentration and 
imprecision was expressed as % relative standard deviation (RSD). Carry-over was 
assessed by injecting blank samples directly after an injection of the highest concentration 
level of the calibrators. Stability of cisplatin was evaluated using three concentration levels of 
QC samples (50, 500, and 8000 ng/mL) in triplicate under the different conditions: 4 h at 
room temperature (about 22 °C), three freeze & thaw cycles from -80 °C to room 
temperature, and 70 days stored at -80 °C. Also, the stability of cisplatin at 37°C at a 
pharmacologically relevant concentration of 3000 ng/mL was studied for 8 h. Autosampler 
(10 °C) stability of extracts was also evaluated for 18 h. The matrix effect (MF) was evaluated 
at low and high concentration levels in drug-free plasma (50 and 8000 ng/mL) from six 
patients and one commercial source by the calculation of internal standard-normalized (IS-
normalized) matrix factor (MF), using Eq. (1). 
 
IS-normalized MF = peak area ratio (analyte/IS) in the presence of matrix ions / peak area 
ratio (analyte/IS) in the absence of matrix ions                                                           (1) 
 
An IS-normalized MF value of one indicates that the analyte and IS are affected to the same 
degree by matrix suppression or enhancement.  The method was regarded as being free of 
relative matrix effect if the coefficient of variation (CV%) of the IS-normalized MF calculated 
from the 7 lots of matrix was less than 15 %. 
 
3. Results and discussion 
 
3.1 Method development  
 
3.1.1 Chromatographic separation 
 
Cisplatin is a neutral and square planar molecule with a log P of -2.27[46]. Since cisplatin is 
an extremely polar compound, obtaining sufficient retention on reversed-phase columns is 
very challenging even with highly aqueous mobile phases. Nevertheless, previous studies for 
the measurement of cisplatin were mainly performed on various brands of C18 columns even 
though a minimal retention factor was shown for cisplatin[8, 31]. As shown in Fig. 1, cisplatin 
is not retained (with a retention factor of 0.16) on a Zorbax Eclipse XDB C18 column (labeled 
as “Column 4”) in an isocratic elution using 7.5 mM formic acid in MeOH/H2O (20:80, v/v) as 
the MP[8]. Ion-pair chromatography was also evaluated for retaining cisplatin by using 0.075 
mM sodium dodecyl sulphate as ion-pair reagent in water (pH 2.5)/methanol (97:3,v/v). 
However, the retention behavior for cisplatin is mostly unaffected (labeled as “Column 3” in 
Fig.1)[31] due to it being neutral. [31]It has been reported that cisplatin has good retention on 
a strong anion-exchange (SAX) column (labeled as “Column 1” in Fig.1) by ion-dipole 
interaction[16], and that it also has satisfactory retention on a porous graphitic carbon (PGC) 
column (labeled as “Column 2” in Fig.1) by dispersion and charge transfer interactions[47]. 
However, the UHPLC formats of SAX and PGC columns are not available, which limits their 
applications in an UHPLC system. Recently, it has been reported that cisplatin is strongly 
retained on a SeQuant ZIC-HILIC column using dimethylformamide as the organic modifier 
for a HLPC-ICP-MS study. The retention mechanism is however not fully understood[32].  
 
In our study, two C18 UHPLC columns were first evaluated for reversed phase 
chromatography. Briefly, a regular Acquity BEH C18 column and an Acquity HSS T3 column, 
which should enhance retention of polar compounds, were evaluated for the separation of 
cisplatin using 0.1% formic acid in H2O/MeOH (95:5, v/v) as the MP. As shown in Fig.1 
labeled as “Column 6” and “Column 7”, a retention factor of less than 0.30 was obtained for 
these two columns, which is consistent with previous findings (“column 3” and “Column 4” in 
Fig.1)[8, 31]. However, there is quite a divergence in the retention factor for cisplatin when 
compared to a more recent publication (labeled as “Column 5” in Fig.1) where they found a 
retention factor of 5.91 on a Zorbax SB C18 column by using 0.1% formic acid in 
water/methanol (40:60, v/v) as the MP[35].  
 
Since cisplatin is poorly retained by reversed-phase chromatography, we then switched to 
HILIC. An unbound silica phase column (Acquity BEH HILIC column) and two identical 
zwitterionic stationary phase columns (SeQuant ZIC-HILIC column and Syncronis HILIC 
column) were evaluated under various chromatographic conditions. As shown in Fig.1 
labeled as “Column 8”, a weak retention (retention factor: 0.96) was obtained on the Acquity 
BEH HILIC column by using ACN/200mM ammonium acetate buffer, pH 4.76 (95/5, v/v). In 
contrast, good retention was obtained for the two zwitterionic stationary phase columns 
(labeled as “Column 9” and “Column 10” in Fig.1). These were therefore selected for further 
method optimization. The SeQuant ZIC-HILIC column provided a stronger retention 
compared to the Syncronis HILIC column, giving a retention factor of 3.17 under the 
chromatographic condition shown in Fig.1 for column 9. Under these initial chromatographic 
conditions, the Syncronis HILIC column only offered weak retention (retention factor: 1.0). 
Based on the information provided by the manufacturer, this difference in chromatographic 
behavior might originate from different bonding density since the carbon content in SeQuant 
ZIC-HILIC column (carbon load: about 10%) is 2-fold higher than that of Syncronis HILIC 
column (carbon load: 5%). Despite providing somewhat better retention, the SeQuant ZIC-
HILIC column comes in HPLC format. The Syncronis HILIC column at the other hand is a 
UHPLC column, thus providing at least equal separations in a shorter time, and was 
therefore preferred for the final method development. 
 
3.1.2 Retention mechanisms 
 
The unbound silica phase is a hydrophilic phase consisting of silanol groups and siloxane 
bridges while the zwitterionic stationary phase carries equal amounts of positive groups 
(quaternary ammonium) and negative groups (sulfonate) bonded in close proximity to the 
silica surface[48, 49]. As a very polar compound, cisplatin is expected to be well retained on 
both of the unbounded silica phase and zwitterionic stationary phase through a combination 
of hydrophilic partitioning, hydrogen bonding,  electrostatic (ionic) interactions, etc. However, 
we found that cisplatin exhibits a weak retention on the unbound silica phase, while excellent 
retention was seen on the zwitterionic stationary phase. Changing the buffer concentration 
(2.5 - 20 mM) did not affect the retention properties of cisplatin on both stationary phases. In 
our opinion, this demonstrates that the electrostatic interaction is not contributing to the 
retention of cisplatin, which is a reasonable assumption since cisplatin is a non-ionizable and 
neutral molecule that has no possibility of interacting via electrostatic interaction.  
 
To understand the nature of the retention mechanism of cisplatin on the zwitterionic 
stationary phase, the effect of the acetonitrile fraction in the mobile phase was varied within a 
range of 69.5 - 95% (v/v). Two common retention models, describing pure partitioning and 
adsorptive interactions[49, 50], respectively, were applied to the HILIC separations.  
 
[49, 50][49, 50]Plots of the logarithm (base 10) of solute retention factor (k) (log k) versus 
volume fraction of water (φ) and log φ, as shown in Fig.2 for cisplatin and the IS, were used 
to decide whether partitioning or adsorption was the predominant retention mechanism. A 
linear regression fit of the log k - φ profiles for the partitioning model results in relatively poor 
coefficients of determination (R²) of 0.9186 and 0.9333 for cisplatin and the IS, respectively. 
Also visual inspection of the curves reveal a non-linear correlation trend. In contrast, the 
linear regression for the adsorptive model provides an excellent fit with R²s for the log k - log 
φ profiles of 0.9997 and 0.9988 for cisplatin and IS respectively. These results seem to point 
out that the retention of cisplatin and the IS are well described by an adsorption mechanism 
(e.g. hydrogen bonds and ion-dipole interactions).  
 
The retention of cisplatin on the zwitterionic stationary phase is likely controlled by ion-dipole 
interactions and not hydrogen bonds. On the one hand, the unbound silica phase has 
hydrogen donor and acceptor properties[48] while providing a very weak retention for 
cisplatin. This indicates that hydrogen bonds are not likely to be an important interaction for 
the retention of cisplatin in HILIC mode. On the other hand, in previous publications, the ion-
dipole interaction was proposed as the retention mechanism for cisplatin on the SAX phase 
containing quaternary ammonium groups[16, 51, 52]. This interpretation is coherent with the 
properties of the zwitterionic stationary phase, where the positively charged quaternary 
ammonium group can interact with cisplatin. Recent studies have demonstrated that at a 
high acetonitrile content in the mobile phase, the water layer surrounding the stationary 
phase is relatively thin and direct interactions such as ion-dipole interactions of solutes and 
the stationary phase are favored in this type of HILIC[48, 50]. According to us, this is why 
cisplatin is retained longer when increasing the acetonitrile content in the mobile phase, by 
assuming ion-dipole interactions as the main retention force in the zwitterionic stationary 
phase.  
 
3.1.3 Development of the sample preparation protocol 
 
Plasma samples need further sample cleanup due to the presence of proteins, and other 
macromolecules. As a very polar compound, cisplatin cannot be extracted directly via liquid-
liquid extraction (LLE) unless derivatization is implemented. Solid phase extraction (SPE) 
which typically yields cleaner extracts is an undesirable poor alternative since cisplatin does 
not retain on most of the solid-phase materials (e.g. C18, CN, and NH2) and a very low 
recovery would be the obvious result[38]. The most efficient and convenient approach to 
analyze cisplatin in plasma is to precipitate the sample proteins with organic solvents. 
However, the endogenous components such as phospholipids (PLs) in the plasma samples 
could cause potential problems for the PPT-based assay.  
 
Phospholipids are the main matrix components and present a major issue when developing 
LC-MS/MS based bioanalytical method because of their ability to cause signal 
suppression/enhancement of the analytes[53-55]. It was reported that significant 
phospholipid-based matrix effects were found for the measurement via LC-MS/MS of polar 
platinum drugs such as carboplatin and oxaliplatin, if adequate sample clean-up was omitted 
for biological samples. This indicates that a suitable sample processing assay is important for 
eliminating the matrix effect for platinum drugs. With regard to the quantitative measurement 
of the matrix effect, the IS-normalized MF was calculated in our study. It should be noted that 
an IS-normalized MF of 1 is not a prerequisite for a reliable method. Highly variable MF in 
individual subjects would be a cause of failing  reproducibility of the analysis[56]. The 
absence of variability in matrix effects between individual subjects (i.e. relative matrix effect) 
is thus a necessity for the robustness of mass spectrometry-based assays[56, 57]. 
Therefore, a thorough study on the presence/absence of relative matrix effect was performed 
before the formal validation experiment.  
 
In our experiments, conventional PPT was first evaluated through precipitating the plasma 
samples with 3-fold volume of ice-cold acetone. Careful selection of a suitable organic 
solvent for PPT is important for obtaining a reliable result. As a nucleophilic solvent, 
acetonitrile can react with cisplatin[9] after a long contact (e.g. 2 hours) thus should be 
avoided. Methanol was also not preferred due to poor cisplatin solubility , and it is a polar 
solvent in the HILIC mode. Acetone was chosen because it does not react with cisplatin and 
it is compatible with the HILIC mode. With an isocratic elution of 5/95 MP A/MP B, the 
separation of the majority of PLs in the deproteinized plasma samples from cisplatin and IS 
was achieved as ascertained via monitoring of the characteristic MRM transitions of PLs[53]. 
However, parts of PLs strongly accumulated on the column and eluted later on during 
subsequent analytical runs, resulting high signal suppression and extremely poor analyte 
responses. Therefore, a column forward flushing procedure was introduced after the isocratic 
elution for the removal of the retained PLs, and this improved chromatography eliminated the 
uncontrollable matrix effects between different injections. Under above described optimal 
conditions, absolute IS normalized MFs for cisplatin ranging from 0.83 to 1.68 were observed 
in plasma samples from different subjects. A significant inconsistency of matrix effects 
between individuals were found (shown in Fig.3 A), resulting a reproducibility problem for the 
assay.  
 
As a newly reported PL removal technique[38, 58], HybridSPE-precipitation was 
subsequently explored for the sample clean-up in order to provide a valid mass 
spectrometry-based assay for cisplatin.  As shown in Fig.3 B, absolute IS normalized MFs 
ranging from 0.87 to 1.20 were observed for cisplatin at a low and high concentration. 
Besides being better compared to those achieved with conventional PPT, relative matrix 
effects were no longer observed, as the CV%’s at low and high concentration levels were 
less than 6%. Therefore, the HybridSPE-precipitation was chosen as the final sample 





3.2.1 Linearity, carryover, specificity, sensitivity, precision and accuracy 
The analysis of the calibrator samples demonstrated that a calibration curve fitted using  a 
quadratic function best described the relationship between cisplatin-to-IS response and 
plasma concentrations. Due to the intended wide concentration range, i.e. the calibration 
curve ranges from 20 to 10000 ng/mL, a log-transformation was required to correct for  
heteroscedasticity. No detectable carry-over for cisplatin and IS was found after the injection 
of the highest calibrator sample, and none of the blank plasma samples gave any 
interferences at the retention regions of the analytes. The limit of quantitation in plasma was 
20 ng/mL, while the detection limit was 2.5 ng/mL. The typical chromatograms of a blank 
plasma sample, a LLOQ level plasma sample, and a real plasma sample obtained after the 
administration of cisplatin are shown in Fig.4. The calculated bias and imprecision for the 
validation samples are listed in Table 2. The within- and between-run bias was always 
between -4.5 - 7.3% and -9.8 - 13.1% of nominal concentrations, and the within- and 
between-run imprecision was between 1.0 - 7.6% and 2.4 - 5.7%, thereby demonstrating that 
the method is precise and accurate.  
 
3.2.2 Stability 
Post extraction plasma samples were stable for 18 h in the autosampler at 10 °C. After three 
freeze and thaw cycles in plasma, 92.7%-103.9% of the analyte was recovered. Studies on 
the stability of cisplatin in plasma, plasma ultrafiltrate, and blood at 37°C have been 
previously investigated[59], while the stability of cisplatin in plasma at room temperature (e.g. 
22 °C) as well as the long term storage stability were scarcely reported. In our study, the 
obtained mean half-lives of degradation for cisplatin in plasma at 22 °C and 37 °C are 5.50 ± 
0.98 h and 1.90 ± 0.03 h, respectively. From this estimated half-life, approximately 16.7% of 
cisplatin will be degraded when the plasma sample is kept at 37 °C for 0.5 h. Similarly, it can 
be calculated that about 6.1% of the cisplatin will be degraded for a plasma sample kept at 
22 °C for 0.5 h. This demonstrates that it is absolutely necessary to maintain a low 
temperature, preferably 0 °C, during the clinical sample collections. In terms of sample 
treatment, it would be safe to sequentially process a small batch of plasma samples within 
approximately 30 min at room temperature or alternatively work on ice altogether. Literature 
reports that cisplatin is stable in plasma at -70 °C for at least 21 days. However, this study 
was conducted at only a single high concentration level (15000 ng/mL) and detailed 
information is lacking. Therefore, a systematical storage stability study of cisplatin, in plasma, 
at -80 °C with low, medium, and high concentration levels for 0, 23, 45, and 70 days was 
conducted. The results demonstrated that cisplatin in plasma is stable for at least 70 days 
when stored at -80 °C with a 95.8%-108.5%  recovery at day 70.  
 
3.3 Comparison with previous methods 
The presented LC-MS/MS assay provides in our view three main advantages over previously 
reported methods for the measurement of cisplatin in biofluids. Firstly, the selectivity is 
superior than that of HPLC-UV and HPLC-ICP-MS, thus eliminating the interference from 
other platinum species in the quantitative measurement of cisplatin in biological samples. 
Secondly, the sample processing is reduced to a simple and high throughput HybridSPE-
PPT treatment, e.g. using 96-well plates, prior to immediate injection of the resulting extract. 
A minimal sample preparation procedure is most important, considering the broad reactivity 
of cisplatin, to achieve the maximum of cisplatin stability. Thirdly, a good sensitivity was 
achieved with limits of detection and quantification being 2.5 and 20 ng/mL. This sensitivity 
achieved is markedly better than the reported HPLC-UV[16, 29] sensitivity and comparable 
with HPLC-ICP-MS[31]. Moreover, the selectivity of both the latter techniques is limited due 
to UV absorption as the detection principle or to the measurement of the Pt as an element 
and not the original organic complex. Taking into consideration the broad reactivity of 
cisplatin in biological samples, it remains a matter of speculation whether the reported 
sensitivity pertains to just intact cisplatin alone or to other PT-containing species.  
 
Previously, an UHPLC-MS/MS method has been reported for the quantification of intact 
cisplatin in rat kidney and liver[35]. In this study, a conventional liquid-liquid extraction (using 
phosphate buffer and ethyl acetate) followed by an evaporation step, was described to 
process the tissue homogenates. The limits of quantification of 5 - 10 ng/mL were achieved 
using an Agilent UHPLC-MS/MS system with 5 µL injections onto a Zorbax SB C18 column. 
As a primary evaluation, a similar procedure based on this reported method was 
implemented in our lab, yet yielded unsatisfied performances. Firstly, as mentioned above, 
retention of cisplatin on the reversed phase reported was not achieved in our study. 
Secondly, the detection limit of cisplatin was about 1 µg/mL on using 1 µL injections into an 
Agilent HPLC 1200 system coupled to a Waters Quattro Ultima triple quadrupole mass 
spectrometer. The weak response observed for cisplatin is in line with other previously 
reported LC-MS/MS cisplatin applications[1, 2, 42]. Thirdly, a similar LLE procedure using 
ethyl acetate was tested for the plasma samples. An extremely low extraction recovery 
(about 0.15%) was found. Albeit that we did not exactly matched the reported procedure by 
omitting incorporate the phosphate buffer, due to its well-known reactivity with cisplatin. The 
observed poor extraction recovery is perfectly in line with previous statements regarding the 
unsuitability of LLE for these platinum drugs due to their high polarity[1, 38].   
 
In the field of assaying the platinum drugs, derivatization is often introduced. It serves a 
number of aims, e.g. to lower the compound polarity for extraction purposes. In our study we 
also investigated derivatization i.e. an on-line derivatization using sodium 
diethyldithiocarbamate (DDTC) as the chelating agent. Our goal was to promote the 
ionization of cisplatin and enhance MS detection. Under our optimized derivatization 
conditions, an about 10-fold increase in sensitivity could be observed in comparison to the 
underivatized approach. Unfortunately, as a non-volatile reagent, DDTC would gradually 
build up on the MS detector sample cone thus gradually causing signal suppression. The 
divert valve switching program and a flow splitting approach were investigated to keep the 
MS interface clean, yet neither was successful in maintaining the initially observed sensitivity 
for an acceptable number of injections.  
 
3.4 Application of the method 
As a proof of concept, the developed UHPLC-MS/MS assay was applied to plasma samples 
from patients with peritoneal carcinoma given a 75 mg/m2 dose of cisplatin via intraperitoneal 
chemoperfusion. The pharmacokinetic profiles of cisplatin in four patients are given in Fig.5, 
demonstrating the practical applicability of this assay for the clinical samples. Interpretation 




A method for reliable, direct quantification of cisplatin in plasma by UHPLC-MS/MS was 
developed and fully validated providing increased selectivity and high throughput over 
previously published methods. The chromatographic separation of the poorly retained 
cisplatin and the required high sensitivity, with respect to its high polarity and weak MS signal 
response, were the prime challenges encountered during the method development. The here 
reported optimal LC-MS/MS conditions provide satisfactory retention and sensitivity for the 
measurement of cisplatin in human plasma as required in present day clinical studies. The 
application of a HybridSPE-precipitation plate proved successful with regard to eliminating 
irreproducible matrix effects. The speed and efficiency of HybridSPE-precipitation in 96-well 
plates with the short LC run time makes this assay suitable for high-throughput analysis of 
clinical studies. Moreover, the short turn around times are favourable in view of the limited 
stability of cisplatin, as has been clearly demonstrated in this work. The method has 
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Table 1 Elution conditions for cisplatin and internal standard. 
 
Time (min) Flow rate (mL/min) % MP A % MP B 
Initial 0.40 5.0 95.0 
1.10 0.40 5.0 95.0 
1.20 1.20 50.0 50.0 
2.50 1.20 50.0 50.0 
2.60 1.20 5.0 95.0 
4.80 1.20 5.0 95.0 








Table 2 Within-run mean imprecision and bias, between-run mean imprecision and 


















20 1 2.7 5.3 3.1 
QC low 50 7.6 5.7 0.2 1 
QC 
medium 
500 7.2 5.5 -3.9 1.3 

















Fig.1 Retention factor comparisons of cisplatin on various analytical columns. Column dead-
time t0 is estimated based on the equation (1): t0 ≈ 5×10
-4 Ld2/F. Where L is the column 
length in mm, d is the column inner diameter in mm, F is the flow rate in mL/min, and t0 is in 
minutes. The retention factor is calculated by equation (2): k = (tR-t0)/t0, where tR is the 
retention time of target analyte. Mobile phase details for the columns: Column 1: 
methanol/0.1 M phosphate buffer (pH 5.0) (55:45, v/v); Column 2: 20 mM HEPES buffer (pH 
9.3); Column 3: 0.075 mM sodium dodecyl sulphate in water (pH 2.5)/methanol (97:3,v/v); 
Column 4: 7.5mM formic acid in MeOH/H2O (20:80, v/v); Column 5: 0.1% formic acid in 
water/methanol (40:60, v/v); Column 6: 0.1% formic acid in H2O/MeOH (95:5, v/v); Column 7: 
0.1% formic acid in H2O/MeOH (95:5, v/v); Column 8: ACN/200mM ammonium acetate 
buffer, pH 4.76 (95/5, v/v); Column 9: MP A (10/85/5, ACN/H2O/200mM ammonium formate 
buffer, pH 3.75) / MP B (95/5, ACN/200mM ammonium formate buffer, pH 3.75) in a ratio of 
25/75; Column 10: MP A (10/85/5, ACN/H2O/100mM ammonium formate buffer, pH 3.75) / 










Fig.2 Plots of the logarithm (base 10) of retention factor (k) (log k) of cisplatin and IS vs. the volume fraction of water (φ) (left panel) and the 
logarithm (base 10) of volume fraction of water (log φ) (right panel) in the mobile phase. Conditions: ACN/water at various percentages; 
ammonium formate buffer on the column, 2.5 mM; pH 3.75; column temperature, 45 °C; flow rate, 0.4 mL/min.  
 
 
Fig.3 Matrix effect for cisplatin in patient plasma samples (Matrix A ~ F) and commercial 
human plasma sample (Matrix G) using conventional PPT and HybridSPE-PPT. The black 
triangles  and black circles represent the low and high concentration levels, respectively. The 
corresponding red signs stand for the mean matrix effect from 6 replications at each 




Fig.4 Representative chromatograms of cisplatin and internal standard (IS) in human plasma. 
Panels (A) and (B): blank human plasma; Panels (C) and (D): blank human plasma fortified 
at lower limit of quantification (LLOQ); Panel (E) authentic plasma sample from a cancer 













Fig.5 Plasma concentration-time profile of cisplatin in four cancer patients after a 75 mg/m2 
dose of cisplatin via intraperitoneal chemoperfusion.  
 
 
 
 
  
 
 
 
 
 
